

The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Additional information on all bank holding companies may be obtained from the National Information Center website at [www.ffiec.gov/nic/](http://www.ffiec.gov/nic/).

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than March 1, 2004.

**A. Federal Reserve Bank of Atlanta**  
(Sue Costello, Vice President) 1000 Peachtree Street, N.E., Atlanta, Georgia 30303:

1. *Hibernia Corporation*, New Orleans, Louisiana; to acquire Coastal Bancorp, Inc., Houston, Texas, and thereby indirectly acquire Coastal Banc SSB, Houston, Texas, and thereby engage in operating a savings and loan, pursuant to section 225.28(b)(4)(ii) of Regulation Y.

Board of Governors of the Federal Reserve System, January 30, 2004.

**Robert deV. Frierson,**

*Deputy Secretary of the Board.*

[FR Doc. 04-2391 Filed 2-4-04; 8:45 am]

BILLING CODE 6210-01-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Notice of Meeting: Secretary's Advisory Committee on Genetics, Health, and Society

Pursuant to Public Law 92-463, notice is hereby given of a meeting of the Secretary's Advisory Committee on Genetics, Health, and Society (SACGHS), U.S. Public Health Service. The meeting will be held from 8:30 a.m. to 5:30 p.m. on March 1, 2004 and 8 a.m. to 5 p.m. on March 2, 2004 at the Marriott Hotel Bethesda on 5151 Pooks Hill Road, in Bethesda, Maryland. The meeting will be open to the public with attendance limited to space available. The meeting also will be webcast.

The first half of the first day will be devoted to a presentation on and discussion of the work of the Committee's Inter-Meeting Task Force and priority setting process. The second half of the first day will consist of presentations on the issue of coverage and reimbursement, a possible priority area for the Committee. The second day will be entirely devoted to discussions around the top priorities and Committee

action in these areas. Time will be provided each day for public comment.

Under authority of 42 U.S.C. 217a, section 222 of the Public Health Service Act, as amended, the Department of Health and Human Services established SACGHS to serve as a public forum for deliberations on the broad range of human health and societal issues raised by the development and use of genetic technologies and, as warranted, to provide advice on these issues.

The draft meeting agenda and other information about SACGHS, including information about access to the webcast, will be available at the following Web site: <http://www4.od.nih.gov/oba/sacghs.htm>. Individuals who wish to provide public comment or who plan to attend the meeting and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the SACGHS Executive Secretary, Ms. Sarah Carr, by telephone at (301) 496-9838 or E-mail at [sc112c@nih.gov](mailto:sc112c@nih.gov). The SACGHS office is located at 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892.

Dated: January 28, 2004.

**LaVerne Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04-2389 Filed 2-4-04; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Guide to Community Preventive Services (GCPS) Task Force

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

*Name:* Task Force on Community Preventive Services

*Times and Dates:*  
8:30 a.m.-6:15 p.m., February 25, 2004  
8 a.m.-1:45 p.m., February 26, 2004

*Place:* The Crowne Plaza Ravinia, 4355 Ashford Dunwoody Road, Atlanta, Georgia 30346-1521, telephone (770) 395-7700.

*Status:* Open to the public, limited only by the space available.

*Purpose:* The mission of the Task Force is to develop and publish a Guide to Community Preventive Services, which is based on the best available scientific evidence and current expertise regarding essential public health and what works in the delivery of those services.

*Matters To Be Discussed:* Agenda items include: briefings on administrative information, health care system interventions for obesity prevention, school based

interventions for tobacco use prevention, environmental approaches to increasing physical activity, multi-component school nutrition programs for improving nutritional behavior and nutritional status of children and adolescents, group education approaches to promoting cancer screening, renewed progress on the Alcohol Chapter, folic acid reviews, implementing the vaccine coverage recommendations: Is the syringe half empty or half full? Violence Chapter.

Agenda items are subject to change as priorities dictate.

*For Further Information Contact:* Peter Briss, M.D., Chief, Community Guide Branch, Division of Prevention Research and Analytic Methods, Epidemiology Program Office, CDC, 4770 Buford Highway, M/S K-73, Atlanta, Georgia, telephone (770) 488-8189.

Persons interested in reserving a space for this meeting should call (770) 488-8189 by close of business on February 23, 2004.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: January 30, 2004.

**Alvin Hall,**

*Director, Management Analysis and Services Office, CDC.*

[FR Doc. 04-2394 Filed 2-4-04; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Human Immunodeficiency Virus Prevention Projects for Community-Based Organizations, Program Announcement Number 04064

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

*Name:* Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Human Immunodeficiency Virus Prevention Projects for Community-Based Organizations, Program Announcement Number 04064.

*Times and Dates:* 1 p.m.-4 p.m., February 22, 2004 (Open); 9 a.m.-5 p.m., February 23, 2004 (Closed); 9 a.m.-5 p.m., February 24, 2004 (Closed); 9 a.m.-5 p.m., February 25, 2004 (Closed); 9 a.m.-5 p.m., February 26, 2004 (Closed); 9 a.m.-5 p.m., February 27, 2004 (Closed); 9 a.m.-12 p.m., February 28, 2004 (Closed).

*Place:* The Westin Atlanta North at Perimeter Center, 7 Concourse Parkway,

Atlanta, GA 30328, Telephone (770) 395-3900.

*Status:* Portions of the meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

*Matters To Be Discussed:* The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcement Number 04064.

*For Further Information Contact:* Beth Wolfe, Resource Funding Analyst, National Center for HIV, STD, and TB Prevention, CDC, 1600 Clifton Road, NE., MS-E07, Atlanta, GA 30333, Telephone (404) 639-8531.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: January 30, 2004.

**Alvin Hall,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 04-2397 Filed 2-4-04; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Prospective Grant of Exclusive License: Diagnostics of Fungal Infections

**AGENCY:** Technology Transfer Office, Centers for Disease Control and Prevention (CDC), Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** This is a notice in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention (CDC), Technology Transfer Office, Department of Health and Human Services (DHHS), is contemplating the grant of a worldwide, limited field of use, exclusive license to practice the inventions embodied in the patent application referred to below to TNB Laboratories, Inc. (TNB) having a place of business in St. Johns, Newfoundland. The patent rights in these inventions have been assigned to the government of the United States of America. The patent application to be licensed is:

*Title:* "Latent Human Tuberculosis Model, Diagnostic Antigens, and Methods of Use," U.S. Patent

Application Serial No.: 10/250,930 (TBC).

*Status:* Pending.  
*Issue Date:* N/A.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

#### Technology

This technology adds a new level of specificity in the identification of Tuberculosis. It can be incorporated into a device to diagnose Latent Human Tuberculosis.

**ADDRESSES:** Requests for a copy of this patent application, inquiries, comments, and other materials relating to the contemplated license should be directed to Andrew Watkins, Director, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop K-79, Atlanta, GA 30341, telephone: (770) 488-8610; facsimile: (770) 488-8615. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by CDC within sixty days of this notice will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. A signed Confidential Disclosure Agreement (available under Forms @ <http://www.cdc.gov/tto>) will be required to receive a copy of any pending patent application.

Dated: January 29, 2004.

**Joseph R. Carter,**

*Deputy Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 04-2396 Filed 2-4-04; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Reporting of Pregnancy Success Rates From Assisted Reproductive Technology Programs

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (DHHS).

**ACTION:** Notice.

**SUMMARY:** The CDC is tasked with implementing the Fertility Clinic Success Rate and Certification Act of

1992 (FCSRCA), Public Law 102-493. As mandated by this law CDC publishes annual reports of pregnancy success rates from ART clinics and embryo laboratory certification status of these clinics. Section 2(a) of Public Law 102-493 (42 U.S.C. 263a -1) requires that each assisted reproductive technology (ART) program shall annually report to the Secretary, through the Centers for Disease Control and Prevention, (a) pregnancy success rates achieved by such ART programs, and (b) the identity of each embryo laboratory used by such ART programs, and whether the laboratory is certified or has applied for such certification under this act. Section (6) states that the Secretary, through the CDC, shall annually publish and distribute to the States and the public, pregnancy success rates reported to the Secretary under section 2(a)(1) and, in the case of an assisted reproductive technology program which failed to report one or more success rates as required under each section, the name of each such program and each pregnancy success rate which the program failed to report.

CDC first implemented the FCSRCA in 1997, and has obtained and published data for ART procedures performed in 1995, 1996, 1997, 1998, 1999 and 2000. Currently, CDC has a contract with the Society for Assisted Reproductive Technology (SART) to annually obtain a copy of their clinic-specific database. The existing contract will be used to obtain and publish data for ART procedures performed in 2001, 2002 and 2003. Details on the current process are outlined in the September 1, 2000 **Federal Register** notice (Volume 65, No. 171, pages 53310-53316).

CDC is currently in the process of selecting a contractor for the 2004, 2005, 2006, 2007, and 2008 data reporting years. We anticipate awarding the contract in February, 2004. Based on that timeframe, we anticipate that the data collection system for 2004 data reporting will be available to clinics in summer, 2004. The new contract to be awarded will cover clinic tracking, data collection and quality assurance and validation processes for ART procedures performed in 2004, 2005, 2006, 2007 and 2008. The data collection process is expected to be similar to the current data collection process (see September 1, 2000 **Federal Register** notice, Volume 65, No. 171, pages 53310-53316).

Under the new contract, the contractor shall furnish all personnel, facilities, equipment, supplies, and materials necessary to assist CDC to produce and publish an annual report of pregnancy success rates and embryo laboratory certification status, as